Work Here?
Overview
Novoic uses artificial intelligence to analyze spoken language to detect early signs of Alzheimer’s disease. It offers a software-based 10-minute speech test that runs on any smart device and is used by medical institutions, with 50+ centers currently adopting the technology. The company aims to extend access to underserved communities where detection is scarce. Revenue comes from selling the software to healthcare providers. Its AI models are validated through Novoic’s own clinical trials and trained on diverse datasets to improve accuracy and fairness.
About Novoic
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
1-10
Company Stage
Seed
Total Funding
$2.6M
Headquarters
London, United Kingdom
Founded
2019
Simplify's Take
What believers are saying
- Mass General AI achieves 99% accuracy in MCI diagnosis from voice storytelling.
- NIA-funded AI predicts MCI-to-Alzheimer's progression with 78.2% accuracy remotely.
- Novoic's abbreviated AI speech test deploys in largest early AD cohorts globally.
What critics are saying
- Wyss Diagnostics' speech test outperforms MRI/PET, captures market in 12-24 months.
- Eli Lilly's Kisunla approval erodes diagnostics demand within 6-12 months.
- OpenAI o3-mini open-sources 82% MCI prediction, undercuts proprietary algorithms immediately.
What makes Novoic unique
- Novoic's Storyteller uses AI story recall for 10-minute Alzheimer's detection anywhere.
- AMYPRED trials (NCT04828122, NCT04928976) outperformed PACC5 in preclinical stages.
- Storyteller integrates in ADNI4 for scalable online screening of underrepresented groups.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2.6M
Below
Industry Average
Funded Over
1 Rounds
Industry standards
Company News
Novoic Raises £2 Million Seed Investment for AI-based Speech Analysis to Detect Neurological Diseases Earlier Anthemis Exponential Ventures leads the round, with participation from APEX Ventures and Entrepreneur First LONDON, July 31, 2020 Novoic, a digital biotechnology company developing speech-based AI algorithms for diagnosis and monitoring of health conditions, today announced it has raised £2.0 million in Seed funding […]
Novoic, a digital biotechnology company developing speech-based AI algorithms for diagnosis and monitoring of health conditions, today announced it has raised £2.0 million in Seed funding to scale up its AI research team and advance its clinical programmes, including in early-stage Alzheimer's and Parkinson's disease.
There are no jobs for Novoic right now.
Find jobs on Simplify and start your career today
About Novoic
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
1-10
Company Stage
Seed
Total Funding
$2.6M
Headquarters
London, United Kingdom
Founded
2019
There are no jobs for Novoic right now.
Find jobs on Simplify and start your career today